PPAR-γ agonists such as rosiglitazoneand pioglitazone belong to the thiazolidinedione (TZD) class and are currentlyin clinical use for lowering glucose levels in diabetes [41, 42]. The gene discussed is PPARG; the disease is diabetes mellitus.